![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
OHB-607 is the recombinant form of human insulin-like growth factor-1 (IGF-1). It is being evaluated for the prevention of bronchopulmonary dysplasia in premature infants.
Lead Product(s): Mecasermin Rinfabate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: OHB-607
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Chiesi Group
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2024
Details:
The agreement aims to develop, manufacture, and commercialise OHB-607 (mecasermin rinfabate), a recombinant version of insulin-like growth factor-1 (IGF-1), being developed to treat complications of extremely premature birth.
Lead Product(s): Mecasermin Rinfabate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: OHB-607
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Chiesi Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 09, 2024